#India #financial results #Mumbai #Piramal Pharma #Q2 FY27

Piramal Pharma Limited's Financial Results for Q2 and H1 FY27

Piramal Pharma Limited has released its financial results for the second quarter (Q2) and the first half (H1) of the fiscal year 2027, demonstrating significant year-on-year growth across its sectors. Operating revenue saw an impressive rise of 28% in Q2 and 23% in H1, backed by strong performance in all three main business segments: Contract Development and Manufacturing (CDMO), Complex Hospital Generics (CHG), and Consumer Healthcare (PCH).

Overall Financial Highlights

• - Consolidated Revenue: For Q2 FY27, revenue reached ₹2,617 crores, up from ₹2,044 crores in Q2 FY26, marking substantial growth.
• - CDMO: Generated ₹1,424 crores, a 36% increase from the previous year, supported by increased demand and operational efficiencies.
• - CHG: Saw revenues rise to ₹849 crores, a 32% year-on-year growth.
• - PCH: Reported ₹359 crores, achieving 15% growth, reflecting continued strength in key brands and e-commerce channels.

Piramal Pharma's EBITDA rose by 72% year-on-year for both Q2 and H1, demonstrating improved operational leverage and cost optimization efforts. The EBITDA margin increased significantly from 11% in the previous year to 14.7% in Q2, aided by enhanced capacity utilization and rigorous execution strategies.

Customer Engagement and Market Confidence

The company added 22 new clients and completed an impressive 110 customer audits in the first half of FY27, showcasing a sustained demand in the competitive landscape. They achieved excellent quality and compliance scores, having successfully undergone 12 regulatory inspections without any adverse findings from the FDA, reflecting the company's commitment to high standards.

Nandini Piramal, Chairperson of Piramal Pharma Limited, expressed confidence in the company's performance, stating that the strong growth in revenue is attributed to robust demand across all sectors, operational discipline, and operational leverage improvements, particularly within their CDMO segment. The CHG business also made significant contributions, adhering to the growing market needs and increasing its share in the vital anesthetic segment.

Future Outlook and Expansion

Following the positive momentum and demand pipeline, Piramal Pharma has upgraded its revenue growth forecast for FY27, now projecting a 19% to 20% increase and expect further enhancements in profitability.

The company’s successful integration of Kenalog® into its CHG segment, which adds to its revenue base, is a key growth driver moving forward. The focus remains on expanding its portfolio with differentiated products and maintaining its market leadership across multiple therapeutic areas.

Furthermore, the consistent support from commercial activities and operational improvements positions Piramal Pharma strongly for a solid performance in the second half of the fiscal year, historically a peak period for financial growth.

As Piramal Pharma continues to invest in innovation and operational capacity, stakeholders can remain optimistic about the company’s trajectory in the evolving pharmaceutical landscape.

In conclusion, Piramal Pharma Limited showcases how strategic growth, rigorous execution, and compliance can yield robust financial results, setting the stage for continued success in the upcoming fiscal quarters.